- Home
- TTNP vs APLM Comparison
TTNP vs APLM Comparison
Compare TTNP & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- APLM
- Stock Information
- Founded
- TTNP 1991
- APLM 2016
- Country
- TTNP United States
- APLM United States
- Employees
- TTNP 4
- APLM N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- APLM Blank Checks
- Sector
- TTNP Health Care
- APLM Finance
- Exchange
- TTNP Nasdaq
- APLM Nasdaq
- Market Cap
- TTNP 5.9M
- APLM 6.9M
- IPO Year
- TTNP 1996
- APLM N/A
- Fundamental
- Price
- TTNP $4.40
- APLM $6.41
- Analyst Decision
- TTNP
- APLM
- Analyst Count
- TTNP 0
- APLM 0
- Target Price
- TTNP N/A
- APLM N/A
- AVG Volume (30 Days)
- TTNP 44.6K
- APLM 4.6K
- Earning Date
- TTNP 08-14-2025
- APLM 08-13-2025
- Dividend Yield
- TTNP N/A
- APLM N/A
- EPS Growth
- TTNP N/A
- APLM N/A
- EPS
- TTNP N/A
- APLM N/A
- Revenue
- TTNP N/A
- APLM $198,000.00
- Revenue This Year
- TTNP N/A
- APLM $415.15
- Revenue Next Year
- TTNP N/A
- APLM N/A
- P/E Ratio
- TTNP N/A
- APLM N/A
- Revenue Growth
- TTNP N/A
- APLM N/A
- 52 Week Low
- TTNP $3.03
- APLM $4.47
- 52 Week High
- TTNP $14.80
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- TTNP 48.35
- APLM 51.61
- Support Level
- TTNP $4.23
- APLM $5.34
- Resistance Level
- TTNP $4.65
- APLM $6.70
- Average True Range (ATR)
- TTNP 0.27
- APLM 0.52
- MACD
- TTNP -0.03
- APLM -0.03
- Stochastic Oscillator
- TTNP 30.67
- APLM 67.65
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.